| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803137401010 | 313740101 | CASMYG PD.C.SO.IN 50MG/VIAL BTx1 VIAL (10ML, TYPE 1 GLASS) x 50mg | 165.45 | 173.55 | 209.72 |
| 05/2018 | 2803137402017 | 313740201 | CASMYG PD.C.SO.IN 70MG/VIAL BTx1 VIAL (10ML, TYPE 1 GLASS) x 70mg | 219.02 | 222.31 | 263.93 |
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Caspofungin inhibits the synthesis of b (1,3)-D-glucan, an essential component of the cell wall of <i>Aspergillus</i> species and <i>Candida</i> species. b (1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.
Side effects include rash, swelling, and nausea (rare)
92% tissue distribution within 36-48 hours after intravenous infusion
9-11 hours
After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.
* 12 mL/min [After single IV administration]